A project led by Ingenza, a worldwide leader in the application of industrial biotechnology and synthetic biology to efficient scalable bioprocesses for the manufacture of chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources.
This project is led by Ingenza, and will use engineered bacteria for the scalable biosynthesis of products traditionally made from petrochemical starting materials. The resulting bioprocess will deliver sustainable manufacturing of valuable industrial chemicals.
Ingenza is a Scottish SME who specialise in the application of industrial biotechnology and synthetic biology, providing efficient scalable bioprocesses to manufacture chemicals, biologics, pharmaceuticals and biofuels, from sustainable sources. Ingenza has a broad and growing customer base across the chemicals, pharmaceuticals, food, feed and fuel industries. Ingenza is led by a management team with over 25 years’ experience in applied bioscience and the development and commercialization of biobased products. In addition to engaging in strategic partnerships to tailor their bioprocess services for clients, Ingenza also license their proprietary bioprocess technologies.
This Exemplar project will be conducted in collaboration with Dr RuAngelie Edrada-Ebel and Dr Nicholas Tucker at the University of Strathclyde who have expertise in metabolomics and transcriptomics respectively. The experience at the University of Strathclyde will provide in-depth analysis and insight into Ingenza’s engineered microbes resulting in a more streamlined industrial process.
Upon completion, as well as providing financial gain to the Scottish economy, this project aims to increase the level of knowledge exchange between industry and academia, with the researcher spending a large part of their time at the Ingenza site. The University of Strathclyde will gain an increased awareness of the commercial realities of the challenges and issues faced by a leading synthetic biology company such as Ingenza. The IBioIC support will enable Ingenza to utilise the expertise and potential benefits that a more detailed transcriptomic and metabolomic evaluation of its engineered cell lines offers.
“This collaboration with Strathclyde University, supported by IBioIC, will help us determine why some of our engineered microbes show superior productivity over others. We can then apply that learning to increase both speed and predictability in achieving optimised industrial processes. IBioIC is a critical enabler in the Scottish biotechnology community”.
Ian Fotheringham, Managing Director of Ingenza Ltd.